Kidney Cancer

Saum Ghodoussipour, MD, provided an in-depth analysis of the RAMPART readout, exploring the DFS benefit of a durvalumab/tremelimumab combination in RCC.

Modulation of angiogenic and immune-related pathways in ccRCC might provide rationale for checkpoint- or VEGFR-TKI–based combinations with HC-7366.

A second expansion phase assessing HC-7366/belzutifan in locally advanced/metastatic renal cell carcinoma is ongoing.

Among 78 responders to ADT plus ARPI treatment who underwent a treatment suspension, 57.7% remained treatment free for 18 months.

RAMPART finds durvalumab after kidney cancer surgery cuts recurrence risk but misses DFS significance; combo therapy shines in highest-risk patients.

Grade 3 or higher TRAEs occurred in 14% of patients treated with NDI-101150, including 1 incidence of grade 4 aplastic anemia across all comers in the study.

The simlukafusp alfa–containing triplet displayed a profile comparable to the safety of each individual drug in this RCC population.

Shikha Gupta, PhD, discussed the biology of tRCC and the mechanistic rationale behind combining CDK4/6 inhibition with selective mTORC1 targeting.

Patrick A. Kenney, MD; and David A. Braun, MD, PhD, discussed parameters they use to determine a patient’s eligibility for cytoreductive nephrectomy.

The safety profiles of the pembrolizumab-based combination regimens were consistent with those observed in previously reported studies.

Phase 2 Cyto-KIK findings showed that a subset of patients with high-risk kidney cancer exhibited responses and underwent monitoring post-cabozantinib.

Experts discussed the clinical implications of the LITESPARK-011 trial of belzutifan plus lenvatinib following a presentation of efficacy findings at ASCO GU.

Experts in genitourinary oncology outlined factors to consider when sequencing immunotherapy, tyrosine kinase inhibitors, and other RCC therapies.

Germline platelet polygenic risk score predicted a 37% higher risk of death in patients with renal cell carcinoma, mediated by sustained thrombocytosis.

The addition of SBRT to an immunotherapy doublet did not significantly affect safety outcomes among patients with de novo metastatic RCC.

Belzutifan plus adjuvant pembrolizumab conferred a 28% reduction in the risk of disease recurrence or death in those with high-risk ccRCC following nephrectomy.

SBRT was considered safe among patients with advanced renal cell carcinoma when added to the immunotherapy combination.

Based on findings from LITESPARK-11, belzutifan/lenvatinib may represent a new option in previously treated renal cell carcinoma.

New biomarker data showed a correlation between magnitude and durability of serum erythropoietin suppression by casdatifan for this group.

Structured exercise interventions may mitigate TRAE, such as fatigue, but data in metastatic RCC are limited.

Irpagratinib demonstrated superior survival among patients with hepatocellular carcinoma who were pretreated with ICIs and mTKIs.

No differences in complication rate were observed between the MIXREAL and control groups among those treated for kidney cancer in the REALITATEM trial.

The median progression-free survival was significantly higher with donor vs placebo fecal microbiota transplantation in this RCC population.

A first-in-human phase 1/2 trial is evaluating the theranostic pair of ITM-91 and ITM-94 in patients with solid tumors.

Pembrolizumab plus belzutifan is the first combination therapy to improve DFS vs pembrolizumab monotherapy in the adjuvant treatment of those with RCC.